Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~* Acute myelogenous leukemia (AML), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years~* AML, in first or subsequent remission or relapsed/refractory disease, age 51 to 60 years of age~* AML with multilineage dysplasia~* Acute lymphoblastic leukemia (ALL), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years~* ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease~* Chronic myeloid leukemia (CML), beyond 2nd chronic phase or in blast crisis~* Myelodysplastic syndrome (MDS), including World Health Organization (WHO)classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS~* MDS with poor long-term survival including myeloid metaplasia and myelofibrosis~* Myeloproliferative disorders~* High-risk non-Hodgkin lymphoma (NHL) in 1st emission~* Relapsed or refractory NHL~* Hodgkin lymphoma (HL) beyond first remission~* Males and females of any ethnic background, 2 to 60 years of age~* Karnofsky Performance Status (KPS) ≥ 70% or Lansky performance status \> 70% for patients \< 16 years of age.~* Related, matched-donor identified \[6/6 human leukocyte antigen (HLA)-A, B and DRB1\]~* Willingness to take oral medications during the transplantation period~* Ability to understand and the willingness to sign a written informed consent document~EXCLUSION CRITERIA~* Prior myeloablative allogeneic or autologous hematopoietic stem cell transplant (HSCT)~* HIV infection~* Pregnant~* Lactating~* Evidence of uncontrolled active infection~* Serum creatinine \> 1.5 mg/dL or 24-hour creatinine clearance \< 50 mL/min~* Direct bilirubin, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 x upper limit of normal (ULN)~* Carbon monoxide diffusing capacity (DlCO) \< 60% predicted (adults) OR and in-room air oxygen saturation \< 92% (children)~* Left ventricular ejection fraction \< 45% (adults) OR shortening fraction \< 26%(children)~* Fasting cholesterol \> 300 mg/dL or Triglycerides \> 300 mg/dL while on lipid-lowering agents.~* Receiving investigational drugs unless cleared by the Principal Investigator (PI).~* Prior malignancies except basal cell carcinoma or treated carcinoma in-situ.~* Cancer treated with curative intent ≤ 5 years (EXCEPTION BY PI DISCRETION) (Cancer treated with curative intent \> 5 years will be allowed).

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Carmustine Etoposide Cyclophosphamide (Type: EXPERIMENTAL): Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
- FTBI + Cyclophosphamide (Type: EXPERIMENTAL): FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).